CryoCell International Inc (CCEL) - Cash Flow Conversion Efficiency

Latest as of August 2025: -0.171x

Based on the latest financial reports, CryoCell International Inc (CCEL) has a cash flow conversion efficiency ratio of -0.171x as of August 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.54 Million) by net assets ($-14.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CryoCell International Inc stock valuation for the company's overall valuation and market capitalisation.

CryoCell International Inc - Cash Flow Conversion Efficiency Trend (1996–2024)

This chart illustrates how CryoCell International Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

CryoCell International Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of CryoCell International Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of CryoCell International Inc to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Goodyear Indonesia Tbk
JK:GDYR
0.057x
Hudson Acquisition I Corp. Common Stock
NASDAQ:HUDA
0.012x
Atico Mining Corporation
V:ATY
0.001x
Sungmoon Elect
KO:014910
0.013x
DIAMINES AND CHEMICALS ORD (BSE)
NSE:DIAMINESQ
-0.045x
ATA Creativity Global
NASDAQ:AACG
0.007x
ECM Libra Financial Group Bhd
KLSE:2143
0.020x
Siab Holdings Bhd
KLSE:0241
0.563x

Annual Cash Flow Conversion Efficiency for CryoCell International Inc (1996–2024)

The table below shows the annual cash flow conversion efficiency of CryoCell International Inc from 1996 to 2024. View CryoCell International Inc stock price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-11-30 $-13.22 Million $6.01 Million -0.455x +43.75%
2023-11-30 $-11.03 Million $8.92 Million -0.809x +85.62%
2022-11-30 $-1.52 Million $8.57 Million -5.624x -396.90%
2021-11-30 $4.18 Million $7.93 Million 1.894x +159.63%
2020-11-30 $-2.67 Million $8.47 Million -3.177x -249.31%
2019-11-30 $-6.95 Million $6.32 Million -0.909x -51.90%
2018-11-30 $-8.91 Million $5.33 Million -0.599x -30.91%
2017-11-30 $-12.50 Million $5.72 Million -0.457x -41.33%
2016-11-30 $-15.41 Million $4.99 Million -0.324x +66.89%
2015-11-30 $-4.96 Million $4.85 Million -0.977x -574.23%
2014-11-30 $-10.73 Million $1.55 Million -0.145x -63.43%
2013-11-30 $-9.27 Million $821.98K -0.089x -121.12%
2012-11-30 $-9.00 Million $360.90K -0.040x +87.95%
2011-11-30 $-2.46 Million $819.12K -0.333x +77.92%
2010-11-30 $-1.55 Million $2.34 Million -1.508x -108.48%
2009-11-30 $-5.18 Million $3.75 Million -0.723x -721.95%
2008-11-30 $-6.98 Million $614.16K -0.088x -117.04%
2007-11-30 $-6.59 Million $-3.40 Million 0.517x +216.84%
2006-11-30 $-2.09 Million $924.90K -0.442x -105.42%
2005-11-30 $394.56K $3.22 Million 8.157x +246.69%
2004-11-30 $-835.75K $4.65 Million -5.561x -1359.26%
2003-11-30 $-3.79 Million $-1.67 Million 0.442x +2061.91%
2002-11-30 $9.87 Million $201.56K 0.020x -76.42%
2001-11-30 $14.52 Million $1.26 Million 0.087x +139.99%
2000-11-30 $6.64 Million $239.53K 0.036x +136.10%
1999-11-30 $5.00 Million $-500.00K -0.100x +85.63%
1998-11-30 $2.30 Million $-1.60 Million -0.696x -115.65%
1997-11-30 $3.10 Million $-1.00 Million -0.323x -199.46%
1996-11-30 $3.70 Million $1.20 Million 0.324x --

About CryoCell International Inc

NYSE MKT:CCEL USA Medical Care Facilities
Market Cap
$27.87 Million
Market Cap Rank
#24180 Global
#5212 in USA
Share Price
$3.46
Change (1 day)
+0.58%
52-Week Range
$2.89 - $4.93
All Time High
$12.07
About

Cryo-Cell International, Inc. engages in cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells, which are used in regenerative medicine to treat a range of conditions. The company manu… Read more